In vitro studies targeting BRAFV600E‐mutant CRC suggest that SHP2 inhibitors (TNO155) can enhance the ability of BRAF and MEK inhibitors to kill tumour cells134 (Table 2). The gene discussed is BRAF; the disease is colorectal carcinoma.